Investigational Drug Details
| Drug ID: | D531 |
| Drug Name: | GLP-1 analogue |
| Synonyms: | -- |
| Type: | Biological drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (JPRN-UMIN000004512) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0671 | JPRN-UMIN000004512 | Not selected | Recruiting | No Results Available | 01/12/2010 | 2 April 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01770 | 34622555 | Diabetes Obes Metab | Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. | Details |
| A01961 | 34552561 | Front Endocrinol (Lausanne) | GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. | Details |
| A04163 | 33732030 | Clin Pharmacol | Clinical Impact of Liraglutide as a Treatment of Obesity. | Details |
| A05535 | 33216087 | Food Funct | Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. | Details |
| A06026 | 33036179 | J Clin Med | One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. | Details |
| A06274 | 32945071 | Diabetes Obes Metab | A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? | Details |
| A06902 | 32704556 | Endocrinol Diabetes Metab | Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. | Details |
| A07726 | 32375182 | Horm Metab Res | Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells. | Details |
| A07888 | 32322207 | Front Pharmacol | Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. | Details |
| A08267 | 32180556 | Mol Metab | Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. | Details |
| A10676 | 31241045 | Gen Physiol Biophys | Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers. | Details |
| A12156 | 30578967 | Biochim Biophys Acta Mol Cell Biol Lipids | Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. | Details |
| A12514 | 30413050 | Pharmaceuticals (Basel) | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? | Details |
| A12630 | 30359962 | Pharmacol Res | Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | Details |
| A15850 | 28681988 | Diabetes Obes Metab | Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. | Details |
| A15862 | 28677333 | Aliment Pharmacol Ther | Review article: new treatments in non-alcoholic fatty liver disease. | Details |
| A18326 | 27208776 | Biochem Biophys Res Commun | GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. | Details |
| A18792 | 26937139 | World J Gastroenterol | Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. | Details |
| A19360 | 26608256 | Lancet | Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. | Details |
| A19727 | 26394161 | J Hepatol | Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. | Details |